Head and Neck Cancer
EA3191
A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
Physician and Research Staff Educational Material
This material is intended for promotional use among health care professionals and is NOT intended for use as patient educational material.
Patient Educational Material
Participating sites should note that the Central Institutional Review Board (CIRB) has approved this material.
Study Chair Dan Zandberg, MD of the University of Pittsburgh/UPMC Hillman Cancer Center discusses EA3191, a clinical trial for patients with head and neck cancer that has come back after initial treatment.
Recruitment/Awareness Promotional Material
Participating sites should note that the Central Institutional Review Board (CIRB) has approved this material. Note: this content can be utilized for site-specific and community outreach (e.g., webpages, informational handouts, posters, etc.) to encourage potential participants to talk with their doctor, or to contact a site where the study is open for more information. The content may not be modified, and the entities who implement this plan (not including clinical staff) must refrain from direct engagement with patients, except to encourage them to speak with their doctor, or to direct them to the trial page on ECOG-ACRIN or Cancer.gov.
